We prospectively compared a single-tube multiplex polymerase chain reaction (PCR) HbH prep and MCV (sensitivity and specificity, respectively: HbH prep, 0.48 and 0.96; MCV, 0.87 and 0.47 
A b s t r a c t

We prospectively compared a single-tube multiplex polymerase chain reaction (PCR) for detecting alphathalassemia with our current approach using 452 blood samples. Initial evaluation of 89 specimens revealed sensitivity and specificity, respectively, for the hemoglobin H inclusion body test (HbH prep) vs PCR for detecting alpha
Thalassemia is a group of genetic disorders characterized by quantitative defects in globin chain synthesis. The subsequent absence or decrease of hemoglobin production results in microcytosis with varying degrees of anemia. These conditions commonly are found in people of Mediterranean, African, Middle Eastern, Indian, Chinese, or Southeast Asian origin. 1 Some evidence suggests that natural selection may have elevated and maintained the high frequency of globin deletions as protection against a severe form of malaria. 2 While the heterozygous state for thalassemia (thalassemia trait) is a benign condition, the homozygous state is associated with more severe disorders that cause substantial morbidity and mortality worldwide.
In the healthy adult, hemoglobin A is the most prevalent form, composed of 2 alpha-globin and 2 beta-globin chains. Two minor hemoglobins also are present: hemoglobin A 2 (2 alpha-and 2 delta-globin chains) and hemoglobin F (2 alphaand 2 gamma-globin chains). There are 4 alpha-globin genes, 2 of which are encoded in tandem (in cis) on each chromosome 16p13.3 3 (αα/αα), and 2 beta-globin genes, 1 on each chromosome 11. beta-Thalassemia often is due to a point mutation or a small deletion or insertion mutation in one of the beta-globin genes, leading to decreased or absent beta-globin chain synthesis. [4] [5] [6] On the other hand, alpha-thalassemia usually is caused by deletion of one or more alpha-globin genes. 4 The rate of synthesis of alpha-globin chains is related to the number of genes deleted. 7 Loss of 1 alpha-globin gene (heterozygous alpha + -thalassemia; -α/αα) results in a silent carrier, not manifesting abnormalities other than mild microcytosis. Loss of 2 alpha-globin genes on 1 chromosome (heterozygous alpha 0 -thalassemia; --/αα), or on opposite chromosomes (homozygous alpha + -thalassemia; -α/-α) may result in a mild microcytic hypochromic anemia. Loss of 3 genes (--/-α) results in an intermediate thalassemia disease state known as hemoglobin H (HbH) disease, and may be associated with reduced growth rate, iron overload unrelated to transfusion history, and other complications. 8 Complete deletion of all 4 alpha-globin genes results in severe hypoxia and anemia in utero (hemoglobin Bart hydrops fetalis; --/--), a lethal condition. 9, 10 The laboratory identification of people with alpha-thalassemia is important for 2 reasons: (1) for the identification of patients of reproductive age who are carriers of serious or life-threatening hemoglobinopathies 8, 11 and (2) for the investigation of microcytic anemia to prevent erroneous and unnecessary medical intervention for iron deficiency.
People with heterozygous alpha 0 -thalassemia and HbH disease are carriers of hemoglobin Bart hydrops fetalis, as they both carry the alpha 0 -thalassemia mutation. Parents who both carry this mutation have a 25% risk of conceiving a fetus with hemoglobin Bart hydrops fetalis. People who are heterozygous and homozygous for alpha + mutations are not carriers of hemoglobin Bart hydrops fetalis but are carriers of HbH disease.
The most common inherited disorder of hemoglobin synthesis is alpha-thalassemia. 12 More than 95% of alphathalassemia cases are deletional. The most common alpha 0 -thalassemia deletions are the Southeast Asian (--SEA ), Mediterranean (--MED ), 20.5 kilobase (kb) (--20.5 ), and Filipino (--FIL ). The most common alpha + -thalassemia deletions are the rightward 3.7 kb (-α 3.7 ) and the leftward 4.2 kb (-α 4.2 ). 1, 3, 13 The --SEA and --FIL deletions are found in Southeast Asian and Chinese populations. A majority of these, more than 90% in most populations, are the --SEA deletion, which occurs with a frequency of 4.5% to 14%. 8 The --MED and --20.5 deletions are found in Mediterranean and Arab populations with a frequency ranging from less than 0.1% to 0.7%. A majority of these, more than 70% in most populations, are the --MED deletion. 1 The -α 3.7 and -α 4.2 deletions are found in Mediterranean, Arab, Indian, Southeast Asian, Chinese, and Oceanian populations, with a frequency ranging from 2.2% to more than 26% in some regions. A majority of these, more than 80% in most populations, are the -α 3.7 deletion. 1 The population served by our facility has a large proportion of people of Asian ethnicity. In Washington State, which has similar demographics to those of southern British Columbia, anomalies of the alpha-globin gene complex were detected in 66% of Asian American patients referred for reproductive reasons. 14 The importance of genotyping to family planning is significant, particularly in Asian ethnic communities, owing to the high frequency of alpha 0 -thalassemia mutations in this population. 9, 10, [14] [15] [16] [17] In general, laboratory diagnosis of alpha 0 -thalassemia carriers is performed by the HbH inclusion body test (HbH prep). This test is laborious, observer-dependent, and reported to have poor sensitivity. 18 Initial screening for other causes of microcytosis, such as iron deficiency, betathalassemia trait, or thalassemic hemoglobin variants, can improve sensitivity. The HbH prep test is seldom positive in alpha + -thalassemia, and laboratory diagnosis in these cases relies on a high index of suspicion, based on a decreased mean corpuscular volume (MCV) and the absence of other causes of microcytosis, followed by DNA studies. Molecular methods for detecting and typing the alpha-thalassemia deletions typically have required the use of Southern blot analysis. 10, 16 The advent of nonradioactive labeling methods improved the safety of the procedure; however, it remains a time-consuming, labor-intensive, and expensive technique. Polymerase chain reaction (PCR) methods developed to specifically amplify individual deletions have required multiple reactions owing to different reagent and cycling conditions appropriate to each deletion. 2, 10, [19] [20] [21] Recently, a single-tube multiplex PCR screen was developed to identify the 6 most common deletional mutations (described in the preceding paragraph). 16 The present study examined the effectiveness of the multiplex PCR for the detection of alphathalassemia compared with our current screening approach of low MCV, exclusion of other causes of microcytosis, and HbH prep.
Materials and Methods
Initial Evaluation
Blood samples from 154 patients that were submitted to MDS Metro Laboratory Services, Burnaby, British Columbia, for thalassemia or hemoglobinopathy investigation were included in the initial evaluation ❚Table 1❚.
Samples from all patients were tested in parallel with existing methods. Group 1 included samples from all patients referred for thalassemia or hemoglobinopathy investigation during a 1-week period. Group 2 included samples selected according to the following criteria: positive HbH prep result or an MCV of 82 µm 3 (82 fL) or less. Whole blood samples were stored at 4°C for up to 1 week before molecular analysis.
Postimplementation Study
Following the initial evaluation, an algorithm was established to select patients with a negative HbH prep result and an MCV of 82 µm 3 (82 fL) or less or diagnosed with other hemoglobinopathies (group 3) for further DNA testing. During this period, an additional 298 samples were submitted for PCR analysis. Samples from patients younger than 4 years were excluded from the study. Whole blood © American Society for Clinical Pathology samples were stored at 4°C for up to 1 week before molecular analysis and were analyzed in batches of at least 6 specimens.
Blood Samples
DNA was extracted from blood samples using the DNA MiniKit (Qiagen, Mississauga, Ontario) following the manufacturer's suggested protocol. Briefly, blood was subjected to Proteinase K digestion in lysis buffer, followed by binding to a silicon membrane and a series of washes in the presence of chaotropic salts. Pure nucleic acid was eluted from the membrane in 200 µL of buffer and subsequently stored at -20°C. This protocol yields between 4 and 12 µg of purified DNA from 200 µL of whole blood.
Current Diagnostic Approach
Blood samples included in the study were subjected to the standard hematologic analysis performed at MDS Metro Laboratory Services. Initial screening tests for thalassemia and the hemoglobinopathies include a CBC count, blood film examination, and high-performance liquid chromatography for the measurement of hemoglobin A 2 and hemoglobin F levels and the detection of hemoglobin variants. We suspect alpha-thalassemia in patients with a decreased MCV if no thalassemic hemoglobinopathy is detected by initial screening. In these cases, an HbH prep is performed by staining RBCs with brilliant cresyl blue and looking for the presence of HbH inclusion bodies (positive HbH prep).
Multiplex PCR Analysis
PCR conditions were as described previously, 16 with minor changes. In brief, PCR was performed using approximately 75 ng of genomic DNA in 25-µL reaction volumes containing 1.5-mmol/L magnesium chloride; 0.2-µmol/L each primer ❚Table 2❚, including 2 primers that target the LIS1 gene and that act as internal controls; 200-µmol/L deoxynucleoside triphosphates; 2.5 U of Taq polymerase (Qiagen); and a proprietary additive provided with the Qiagen Taq polymerase (Q Solution). Cycling was carried out on a 9600 thermal cycler (Perkin-Elmer, Foster City, CA) with an initial 5-minute denaturation at 95°C, followed by 30 cycles at 97°C for 45 seconds, 60°C for 75 seconds, and 72°C for 150 seconds and a final extension at 72°C for 5 minutes. Following amplification, 10-µL aliquots were mixed with bromphenol blue-xylene cyanol loading dye (Sigma-Aldrich, Oakville, Ontario) and electrophoresed through an 0.8% agarose gel (Bio-Rad, Mississauga) in 1× Tris-borate-EDTA buffer for 1 hour at 5-6 V/cm. The gel was prepared with ethidium bromide (Sigma-Aldrich), and once electrophoresis was complete, the amplified products were visualized on a UV transilluminator housed in the GelDoc system (Bio-Rad). Images were processed on the computer and printed on a laser printer for documentation.
Results
The PCR analysis was performed as described on 452 peripheral blood samples (154 in the initial evaluation of the method and 298 in subsequent analyses of suggestive but unconfirmed cases). All samples were amplified and genotyped independently of the hematologic evaluation. In all cases, the internal control was amplified successfully. Appropriate alpha-globin genotypes were assigned as shown in ❚Table 3❚ (initial evaluation) and ❚Table 4❚ (postimplementation study). 
Initial Evaluation
The initial evaluation analyzed 154 specimens, divided into 2 groups. In group 1, which consisted of 89 samples, standard hematologic methods diagnosed 13 alpha-thalassemia cases, 15 beta-thalassemia cases, and 1 case of hemoglobin H disease. Of the remaining 60 specimens, 34 were hematologically normal, while 26 had microcytosis (MCV, 82 µm 3 [82 fL] or less) but could not be confirmed as either alpha-or beta-thalassemia cases by HbH prep or by high-performance liquid chromatography. In this cohort of patients, the carrier rate for alphathalassemia was 16% (14/89).
PCR analysis of group 1 confirmed the diagnosis of alpha 0 -thalassemia in 10 of 13 cases that had an HbH prep result consistent with heterozygous alpha 0 -thalassemia. All specimens carried the --SEA deletion; the remaining 3 cases were negative by PCR. One patient with beta-thalassemiatrait also was found to be a carrier of the --SEA deletion. The 1 patient diagnosed by HbH prep with hemoglobin H disease had the common genotype (--SEA /-α 3.7 ). Various deletions of the alpha-globin genes were identified in 8 of 26 cases with no detectable hemoglobinopathy and an MCV of 82 µm 3 (82 fL) or less. Genotypes detected were as follows: --SEA /αα, 2; -α 3.7 /αα, 2; -α 3.7 /-α 3.7 , 3; and -α 3.7 /-α 4.2 , 1. Of 34 patients with an MCV of more than 82 µm 3 (>82 fL), 3 were heterozygous carriers for the 3.7-kb single gene deletion (-α 3.7 /αα). HbH prep and PCR results for group 1 are shown in Table 3 . The sensitivity and specificity of the HbH prep compared with the multiplex PCR for the detection of alpha 0 -thalassemia carriers were 0.79 and 0.96, respectively. The sensitivity and specificity of the HbH prep compared with the multiplex PCR for detection of all alphathalassemia genotypes were 0.48 and 0.96, respectively. The sensitivity and specificity of an MCV of 82 µm 3 (82 fL) or less for alpha 0 -thalassemia carriers were 1.0 and 0.45, respectively. The sensitivity and specificity of an MCV of 82 µm 3 (82 fL) or less compared with the multiplex PCR for all alpha-thalassemia genotypes detected were 0.87 and 0.47, respectively.
In group 2, 65 samples were selected for PCR analysis based on positive HbH prep results or an MCV of 82 µm 3 (82 fL) or less. Standard hematologic methods diagnosed 36 cases of alpha-thalassemia and 9 cases of beta-thalassemia trait. In 20 specimens, indices were suggestive of thalassemia, ie, no detectable hemoglobinopathy and an MCV of 82 µm 3 (82 fL) or less.
PCR analysis of group 2 samples confirmed the diagnosis of alpha 0 -thalassemia in 34 of 36 cases with an HbH prep result consistent with heterozygous alpha 0 -thalassemia. All but 1 patient carried the --SEA deletion, and that patient carried the --MED deletion. None of the beta-thalassemia cases exhibited deletions in the alpha-globin gene complex. Various alpha-globin gene deletions were detected in 7 of the 20 cases that were suggestive of thalassemia. Genotypes detected were as follows: --SEA /αα, 1; -α 3.7 /αα, 5; and -α 3.7 /-α 3.7 , 1. HbH prep and PCR results are shown in Table 3 .
The sensitivity and specificity of the HbH prep compared with the multiplex PCR for the detection of alpha 0 -thalassemia carriers were 0.97 and 0.93, respectively. The sensitivity and specificity of the HbH prep compared with the multiplex PCR for all alpha-thalassemia genotypes detected were 0.83 and 0.92, respectively.
Postimplementation Study
The postimplementation study analyzed 298 specimens (group 3). Of these, standard hematologic methods revealed 96 cases of beta-thalassemia trait (Table 4) , 12 other hemoglobinopathies, and 190 specimens with an MCV of 82 µm 3 (82 fL) or less in which no hemoglobinopathy was detected.
PCR analysis identified alpha-globin deletions in 11 (11%) of 96 beta-thalassemia cases (--SEA /αα, 4 cases; -α 3.7 /αα, 7 cases). Among the 12 cases with other diagnosed hemoglobinopathies, 9 (75%) also carried alpha-globin gene deletions: --SEA /αα, 4; -α 3.7 /αα, 3; and -α 3.7 /-α 3.7 , 2. PCR analysis of the 190 cases without a detectable hemoglobinopathy showed that 91 (47.9%) were carriers of alphaglobin deletion mutations: --SEA /αα, 26; -α 3.7 /αα, 45; -α 3.7 /-α 3.7 , 13; -α 3.7 /-α 4.2 , 5; and -α 4.2 /αα, 2.
Discussion
We evaluated the effectiveness of a multiplex PCR targeting 6 common alpha-globin deletions compared with a low MCV and a positive HbH prep result in the diagnosis of alpha-thalassemia when other causes of microcytosis had been excluded. In an analysis of unselected specimens referred for thalassemia or hemoglobinopathy investigation (group 1), the sensitivity and specificity of the HbH prep compared with the multiplex PCR for detection of alpha 0 -thalassemia were 0.79 and 0.96, respectively. The sensitivity of the HbH prep was significantly lower for detection of all alpha-thalassemia genotypes (0.48), although the specificity remained high. It is well recognized that the HbH prep result is seldom positive in alpha + -thalassemia cases 18 ; thus, the low sensitivity for detection of all alpha-globin deletions was not unexpected. In the follow-up evaluation of 298 additional cases (group 3) with suggestive alpha-thalassemia indices and a negative HbH prep result or diagnosed with another hemoglobinopathy, 111 cases of alpha-globin gene deletions (37.2%) were observed. Of these, 34 patients (30.6%) were found to have alpha 0 -thalassemia. These data clearly demonstrate the superior effectiveness of the multiplex PCR over the HbH prep in the diagnosis of alpha 0 -thalassemia and other alpha-thalassemia genotypes.
Use of MCV cutoff levels is an established method for selecting presumptive alpha-thalassemia cases. In the initial evaluation of 89 specimens submitted for thalassemia or hemoglobinopathy investigation (group 1), the sensitivity and specificity of an MCV of 82 µm 3 (82 fL) or less compared with the multiplex PCR for detection of alpha 0 -thalassemia carriers were 1.0 and 0.45, respectively. The sensitivity for detection of all alpha-thalassemia genotypes was 0.87, while specificity remained low (0.47). Three patients in this group, with an MCV of more than 82 µm 3 (>82 fL), had the -α 3.7 /αα genotype. Use of the MCV cutoff of 82 µm 3 (82 fL) would preclude diagnosis of these cases as alpha-thalassemia trait. We found that the majority of patients with a single gene deletion genotype also had a low MCV, and only 3 patients in this group were hematologically normal. However, since these patients are not carriers for hemoglobin Bart hydrops fetalis and would not be misdiagnosed with iron deficiency anemia, the clinical significance of not diagnosing them is low. Use of an MCV of 82 µm 3 (82 fL) or less is a safe and effective means of selecting patients for further investigation for alpha-thalassemia.
Selection of specimens by an MCV of 82 µm 3 (82 fL) or less improved the sensitivity of the HbH prep compared with the multiplex PCR. In an analysis of 65 samples with an MCV of 82 µm 3 (82 fL) or less (group 1), the sensitivity of the HbH prep for detection of alpha 0 -thalassemia was 0.97, and the specificity also was high (0.93). Detection of all alpha-thalassemia genotypes also was improved, with a sensitivity of 0.83 and a specificity that remained relatively unchanged (0.92). Application of this strategy produced a significant improvement in the sensitivity of the HbH prep for the diagnosis of alpha 0 -thalassemia, while maintaining high specificity. This suggests that the HbH prep is useful in laboratories where PCR is not available. It also suggests that the HbH prep is valuable in laboratories that have PCR capabilities, as it can assist in diagnosing alpha 0 -thalassemia cases without the need for subjecting all specimens with an MCV of 82 µm 3 (82 fL) or less to PCR analysis.
In the initial evaluation (groups 1 and 2), 5 cases with positive HbH prep results failed to demonstrate any of the common deletional mutations included in the multiplex PCR. These patients likely have a nondeletional form of alpha-thalassemia, a deletional form not included in the PCR, or an acquired form of alpha-thalassemia. Detection of these cases by the HbH prep supports the value of HbH inclusion body screening, even in laboratories with DNA diagnostic capabilities.
Analysis of 298 specimens (group 3) with suggestive alpha-thalassemia indices or another diagnosed hemoglobinopathy identified 111 patients (37.2%) with alpha-globin gene deletions that were undetected by the HbH prep. Of these, 34 (30.6%) had the --SEA /αα genotype, 7 of which occurred in patients with other hemoglobinopathies that cause microcytosis. These data demonstrate the requirement for DNA testing for alpha-thalassemia in all patients with microcytosis who undergo prenatal screening regardless of other hemoglobinopathies detected.
Only 1 --MED deletion was detected during the present study, and neither the --FIL nor the --20.5 deletion was observed. Although the published prevalence of these deletions is low, 1 the population served by this laboratory is diverse and includes ethnic groups in which these deletions may occur. Targeted DNA investigation is a potential option if the ethnicity of the patient is known; however, this information is not readily available to us and cannot be presumed. In addition, multiracial births may present mutations not expected in a given ethnic group. 8 Use of additional primers in a single multiplex reaction has little effect on the cost of providing the service. The largest component of any DNAbased method is labor. Thus, providing a single, inclusive PCR approach is substantially more cost-effective than offering a limited, more targeted approach, with additional follow-up in cases with negative results. The inclusion of the primers targeting the 6 common deletions in a single multiplex PCR is a cost-effective and efficient means for providing the best possible adjunct method to our diagnostic capabilities.
Our results demonstrate that the multiplex PCR is a useful addition to the diagnostic strategy for detection of alpha-thalassemia. Initial screening by a low MCV, an HbH prep, and the absence of other hemoglobinopathies can be followed by DNA studies for known common alpha-globin genotypes. The use of a low MCV plus the HbH prep is sufficiently sensitive for the diagnosis of alpha 0 -thalassemia cases in laboratories without molecular capabilities. However, this multiplex PCR is an efficient addition to the testing algorithm in a clinical laboratory for the investigation of thalassemia or hemoglobinopathy cases. In addition, the multiplex PCR is a valuable tool for screening all patients with microcytosis undergoing prenatal evaluation, regardless of other diagnosed hemoglobinopathies.
Conclusions
The multiplex PCR used in the present study was more effective for the diagnosis of alpha-thalassemia than the HbH prep. The data shown here demonstrate that using an MCV threshold of 82 µm 3 (82 fL) or less is an effective means of selecting patients for alpha-thalassemia investigation. Furthermore, it substantially increases the sensitivity of the HbH prep for the detection of alpha 0 -thalassemia. The HbH prep, when used in conjunction with a low MCV, continues to have value for the diagnosis of alpha 0 -thalassemia in laboratories where PCR methods are not available. In addition, the HbH prep continues to be useful for the detection of nondeletional, rare deletional, and acquired forms of alpha-thalassemia in laboratories that perform PCR testing. Given the cost-efficiency of targeting multiple deletions, the ethnic variability of the population served by this laboratory, and the good sensitivity of the HbH prep when used in conjunction with a low MCV, a multitiered strategy that involves conventional testing including the HbH prep, followed by DNA studies using the multiplex described herein can provide an efficient method for the diagnosis of alpha-thalassemia. Our data demonstrate that no single method is capable of identifying all carriers of alpha-thalassemia, and the diagnostic approach must include a combination of techniques. Our results also underscore the importance of DNA studies in all patients with microcytosis undergoing a prenatal workup for thalassemia, regardless of other hemoglobinopathies detected.
